SHANGHAI, March 23, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has ...

SHANGHAI, March 20, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced it has been ...

WuXi Biologics differentiates itself from other well-established global contract development and manufacturing organizations with its "follow and win the molecule" and global dual sourcing strategies.

Based on data reported through the CDP 2024 Assessment Questionnaire, WuXi Biologics achieved a score of "A" for Water Security, standing out among over 25,000 companies evaluated. As a ...

Based on data reported through the CDP 2024 Assessment Questionnaire, WuXi Biologics achieved a score of "A" for Water Security, standing out among over 25,000 companies evaluated. As a contributor to ...

SHANGHAI, March 23, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has received ...

SHANGHAI, March 20, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced it has been ...

The company was ranked top in its industry and received a Top 1% S&P Global Corporate Sustainability Assessment (CSA) Score, marking the third year WuXi Biologics has received this highest level ...

Talents People are WuXi Biologics' greatest assets. As of December 31, 2024, the Group's total employee count reached 12,575, including 4,383 scientists, with a key talent retention rate of 95.8%. The ...